EXTH-25. THE CSF PENETRATION OF THE PROCASPASE-ACTIVATING COMPOUND (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN A NONHUMAN PRIMATE CSF ACCESS MODEL

BACKGROUND: The synergistic activity of temozolomide (TMZ) administered in combination with procaspase-activating compound (PAC-1) has been reported in pre-clinical mouse models and canine patients, leading to clinical trials in adults with glioblastoma. To optimize pediatric clinical trial design,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Lester McCully, Cynthia, Shankarappa, Priya, Garcia, Rafael Cruz, Peer, Cody, Zakharov, Alexander, Fischer, James, Lyubimov, Alexander, Hergenrother, Paul, Thomas, Marvin, Figg, William, Warren, Katherine
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Preclinical Experimental Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651507/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.379
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares